Patrick Soon-Shiong, Executive Chairman at ImmunityBio, shared on X:
“Journal of Urology publication of our updated 100 patients with long-term data in BCG unresponsive non muscle invasive bladder cancer. Responses extending beyond 53 months! 84% cystectomy free survival at 36 months.
NK cells matters. Chemotherapy reduces lymphocytes.
Next, BCG naive in non muscle invasive bladder cancer.”
This can be interesting:
ANKTIVA® Approved in Macau for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer 2026
